Fintel reports that on February 6, 2025, HC Wainwright & Co. initiated coverage of Harrow (NasdaqGM:HROW) with a Buy ...

H.C. Wainwright reaffirmed a positive stance on Altimmune (NASDAQ:ALT) shares, maintaining a Buy rating and a $12.00 price target. Currently trading at $6.99 with a market capitalization of $497 ...

H.C. Wainwright raised the firm’s price target on Kura Oncology (KURA) to $40 from $37 and keeps a Buy rating on the shares. The firm says the ...

HC Wainwright reissued their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA – Free Report) in a research report ...

H.C. Wainwright initiated coverage of Harrow (HROW) with a Buy rating and $57 price target Harrow is a commercial-stage company focused on the ...

Analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued to investors on Monday, February 3rd. HC Wainwright analyst S.

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

H.C. Wainwright analyst Arthur He initiated coverage of Nektar (NKTR) with a Buy rating and $6.50 price target Nektar is a clinical-stage biopharmaceutical company focused on developing innovative ...